SIREN : 492168208
ROSKIL MEDICA is a French company founded 19 years ago, specialized in the sector Gestion de fonds. Based in CHATOU (78400), this company of category PME shows in 2024 a net income negative of -416€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-04-18
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Kennzahl | 2024 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Umsatz | N/C | N/C | N/C | N/C | N/C | N/C | N/C | N/C | N/C |
| Nettoergebnis | -416 € | -316 € | 8 641 € | 181 187 € | 6 703 € | 303 € | 11 992 € | -129 € | -389 € |
| EBITDA | -416 € | -316 € | -861 € | -263 € | -300 € | 152 € | -494 € | -132 € | -393 € |
| Nettomarge | N/C | N/C | N/C | N/C | N/C | N/C | N/C | N/C | N/C |
In 2024, ROSKIL MEDICA records a net loss of 416 €. This deficit will reduce equity on the balance sheet.
-416 €
-416 €
-416 €
The debt ratio (= Financial debt / Equity x 100) stands at -697%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches -17%. Low autonomy: the company heavily depends on external financing (banks, suppliers).
-696.661%
-16.741%
-876.118
In 2024, the debt ratio of ROSKIL MEDICA (-696.66) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.
In 2024, the financial autonomy of ROSKIL MEDICA (-16.7%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2024, the repayment capacity of ROSKIL MEDICA (-876.12) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.
The liquidity ratio (= Current assets / Current liabilities) stands at 206.96. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
206.964
0.0
In 2024, the liquidity ratio of ROSKIL MEDICA (206.96) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
In 2024, the interest coverage of ROSKIL MEDICA (0.0x) ranks above the median of the sector. This ratio indicates how many times operating income covers interest expenses. This comfortable position offers an appreciable safety margin.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 0 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 259 days. Excellent situation: suppliers finance 259 days of the operating cycle (retail model).
0 €
0 j
259 j
0 j
Compare ROSKIL MEDICA with other companies in the same sector:
The revenue of ROSKIL MEDICA is not publicly disclosed (confidential accounts filed with INPI).
ROSKIL MEDICA recorded a net loss in 2024.
The headquarters of ROSKIL MEDICA is located in CHATOU (78400), in the department Yvelines.
The tax return of ROSKIL MEDICA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
ROSKIL MEDICA operates in the sector Gestion de fonds (NAF code 66.30Z). See the 'Sector positioning' section above to compare the company with its competitors.